Teaching NeuroImages: Primary diffuse large B-cell lymphoma of the cranial vault
D. Renard, MD,
C. Campello, MD,
O. Beraru, MD,
P. Bouillot, MD and
P. Labauge, MD, PhD
From the Department of Neurology (D.R., C.C., O.B., P.L.), CHU Nîmes, Hôpital Caremeau; and Department of Neurosurgery (P.B.), Clinique des Franciscaines, Nîmes, France.
Address correspondence and reprint requests to Dr. Dimitri Renard, Department of Neurology, CHU Nîmes, Hôpital Caremeau, Place du Pr Debré, 30029 Nîmes Cedex 4, France dimitrirenard{at}hotmail.com
A 67-year-old woman presented with a painful right-sided scalpswelling. Brain imaging showed an intracranial and extracranialfrontal mass lesion associated with local cranial bone destruction(figure). The radiologic differential diagnosis included malignantmeningioma, primary bone tumor, and bone metastasis. Thoracic,abdominal, pelvic, and orbital CT scan, bone scintigraphy, whole-bodyfluorodeoxyglucose PET, bone marrow biopsy, lumbar puncture,and ophthalmologic examination (including slit lamp examination)showed no other lesions. Open lesion biopsy revealed a diffusemalignant large B-cell non-Hodgkin lymphoma of the dura materand cranial bone. Six cycles of R-CHOP (rituximab with cyclophosphamide,doxorubicin, vincristine, and prednisone) regimen was started.Primary bone (most frequently non-Hodgkin) lymphoma are rare.1,2In our case, associated dura mater involvement (which seemedto be secondary) was seen on both brain imaging and histology.Primary bone tumors often have a favorable outcome, especiallywhen treated by combined modality therapy. Clinical stage isthe most important prognostic variable in predicting overallsurvival.
Figure Brain images showing an intracranial and extracranial frontal mass lesion associated with local cranial bone destruction
Brain CT showing a slightly hyperintense intracranial and extracranial frontal mass lesion (A) with homogeneous enhancement after contrast injection (B), associated with local cranial bone destruction (C). This lesion was isointense on T1-weighted (D) and T2-weighted (E) MRI. Gadolinium-enhanced T1 sequences showed strong, slightly heterogeneous enhancement (F).